Pfizer Reports Q1 2026 Revenues of $14.5B with 7% Operational Growth Excluding COVID-19 Products, Reaffirms Full-Year Guidance
Pfizer Inc. (NYSE: PFE) reported first quarter 2026 financial results on May 5, 2026, with...
May 2026
China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026
The National Health Commission (NHC) of China has implemented the Guiding Principles for Defining Biomedical...
UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases
UCB (EBR: UCB) announced on May 3, 2026, a definitive agreement to acquire Candid Therapeutics...
AstraZeneca’s Truqap Receives Positive ODAC Recommendation for PTEN-Deficient mHSPC Based on CAPItello-281 Trial Data
AstraZeneca plc (NYSE: AZN) announced that the US Food and Drug Administration’s (FDA) Oncologic Drugs...
SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease
SiranBio, a Suzhou-based siRNA drug developer, announced a strategic licensing agreement with GlaxoSmithKline plc (GSK;...